Control of quality and safe use of medicines is a priority direction in the development of health care worldwide.

Concern about patients' safety is a priority for Nanolek, both at the stage of drug development, and at the stage when the drug has already been registered and is widely used in medical practice.

In accordance with the Russian legislation, international standards and ethical principles, the company monitors the safety of its medicinal products in order to detect potential adverse reactions and complaints associated with the use of drugs produced by Nanolek LLC.

The main objectives of pharmacovigilance is the earliest possible identification of previously unknown safety-related issues of medicinal products, the identification of the increase in the incidence of adverse reactions, the determination of risk factors in the application of the drug and quantitative assessment, the monitoring of the "risk-benefit" ratio in the application of a drug in order to protect patients from excessive risks in terms of receiving a potential positive effect from the drug use.

Safety monitoring makes it possible not only to promptly inform regulatory authorities and health professionals of adverse reactions in the application of the company's products, but also helps us to consider this information while improving our products.

Please immediately inform us if you became aware of:

  • claims to the quality of products;
  • adverse events occurred during the use of drugs;
  • cases of individual intolerance; cases of overdose;
  • interaction with other drugs or with food products; use of drugs for not permitted purposes;
  • the absence of drug efficiency; use of drugs during pregnancy and / or lactation;
  • influence of drugs to which individuals are exposed during their professional activities;
  • unexpected therapeutic effects of drugs.

To receive detailed information, you can download an application form, fill it out and send it in any way convenient for you:

  • by fax to: +7 (495) 648 26 87
  • by by email to:
  • by mail to: – 127055, City of Moscow, Butyrskiy Val, 68/70, build. 1. Business center "Baker Plaza", 4 floor, office 45